Jan 10 (Reuters) - Royalty Pharma RPRX.O said on Friday it would pay about $1.1 billion to acquire RP Management, an organization that manages its operations as the healthcare firm seeks to simplify corporate structure.
Royalty Pharma buys royalties of future drugs from academic labs and biotechnology companies, which in turn use the cash to fund their research.
(Reporting by Bhanvi Satija in Bengaluru; Editing by Shilpi Majumdar)
((Bhanvi.Satija@thomsonreuters.com; Outside U.S. +91 9873062788;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.